BidaskClub Lowers NxStage Medical (NXTM) to Sell

NxStage Medical (NASDAQ:NXTM) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a report released on Thursday.

Other equities analysts have also issued research reports about the stock. ValuEngine raised shares of NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday, October 12th. Zacks Investment Research raised shares of NxStage Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, October 10th.

Shares of NASDAQ:NXTM traded up $0.18 during trading on Thursday, reaching $28.90. The stock had a trading volume of 186,205 shares, compared to its average volume of 667,112. NxStage Medical has a 52 week low of $22.70 and a 52 week high of $29.26. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -131.36 and a beta of 0.07.

NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings results on Wednesday, November 7th. The medical device company reported $0.01 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.03. NxStage Medical had a negative net margin of 1.29% and a negative return on equity of 2.50%. The company had revenue of $108.12 million for the quarter, compared to analyst estimates of $108.07 million. As a group, research analysts expect that NxStage Medical will post 0.05 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in NXTM. Teachers Advisors LLC increased its position in NxStage Medical by 0.4% during the third quarter. Teachers Advisors LLC now owns 123,526 shares of the medical device company’s stock worth $3,445,000 after acquiring an additional 508 shares during the period. Vanguard Group Inc increased its position in NxStage Medical by 1.7% during the third quarter. Vanguard Group Inc now owns 5,970,746 shares of the medical device company’s stock worth $166,523,000 after acquiring an additional 101,806 shares during the period. Marshall Wace LLP increased its position in NxStage Medical by 31.4% during the third quarter. Marshall Wace LLP now owns 1,148,542 shares of the medical device company’s stock worth $32,033,000 after acquiring an additional 274,664 shares during the period. Vanguard Group Inc. increased its position in NxStage Medical by 1.7% during the third quarter. Vanguard Group Inc. now owns 5,970,746 shares of the medical device company’s stock worth $166,523,000 after acquiring an additional 101,806 shares during the period. Finally, Rehmann Capital Advisory Group increased its position in NxStage Medical by 2,689.0% during the third quarter. Rehmann Capital Advisory Group now owns 5,578 shares of the medical device company’s stock worth $200,000 after acquiring an additional 5,378 shares during the period. 83.49% of the stock is currently owned by institutional investors.

About NxStage Medical

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Read More: Why do companies issue stock splits?

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply